Search

everythinglearnresearchcommunity

for

Search:↓

Betamethasone dipropionate reduced skin thickness, fish oil increased it, and combined treatment had no significant effect.

Tofacitinib and adalimumab are promising treatments for cicatricial alopecia with few side effects.

Tofacitinib helped regrow hair in a woman with alopecia areata.

Intensive immunosuppression can reduce relapse rates in multiple sclerosis patients, despite some side effects.

The new anti-acne treatment HA-P5 effectively reduces acne by targeting two key receptors and avoids an enzyme that can hinder treatment.

Deuruxolitinib is FDA-approved for treating severe alopecia areata.

Oral tofacitinib shows promise in treating atopic dermatitis and alopecia areata, but only slight improvement in vitiligo.

Deuruxolitinib effectively treats alopecia areata but may cause manageable side effects.

Ruxolitinib helps protect skin stem cells and keeps skin healthy in mice with skin GVHD.

Rezpegaldesleukin shows promise for treating severe alopecia areata.

Omalizumab is generally safe for chronic urticaria, but hair loss is a common side effect.

Blocking EGFR in skin cells doesn't majorly increase inflammation markers.

Ocrelizumab may cause pancreatitis in some patients.

Deucravacitinib improves symptoms and reduces inflammation in Lichen Planopilaris.

Combining baricitinib with golimumab helped regrow hair in a patient with ankylosing spondylitis and alopecia areata.

Tofacitinib effectively treated both ulcerative colitis and alopecia areata in two patients.

Upadacitinib improved hair regrowth and quality of life in alopecia areata patients with minimal side effects.

Upadacitinib effectively treats severe alopecia areata and is safe.

JAK inhibitors show promise for treating various skin diseases.

Deuruxolitinib improves hair regrowth in alopecia areata but needs more safety research.

Etanercept is safe and may help improve hidradenitis suppurativa, but more research is needed.

Pioglitazone, Trimipramine, and Dimetindene may be repurposed to treat psoriasis.

Nemolizumab improved both severe atopic dermatitis and alopecia areata in one patient.

Upadacitinib is safe and effective for treating alopecia areata and atopic dermatitis in children.

Adalimumab was safe but mostly ineffective for severe alopecia areata.

Brepocitinib improves cicatricial alopecia and reduces key immune markers.

The new delivery system improves Alzheimer's symptoms by releasing Huperzine A slowly and effectively.

The cream with xyloglucan, pea protein, and cactus extract works as well as the standard treatment for psoriasis and is well-tolerated.